TCRX in vivo TCR therapies move to IND-enabling stage
TCRX says two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities. Preclinical data and regulatory updates are expected in Q1 2027, with a phase I trial planned for Q4 2027.
Two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027.
The heme malignancy program showed strong early results but is paused pending partnerships, while the autoim…